Advertisement

Kamada Will Supply COVID-19 Treatment to Israel

Kamada Will Supply COVID-19 Treatment to Israel

Israeli biotech Kamada (NASDAQ: KMDA) announced a supply agreement with the Israeli Ministry of Health for its investigational COVID-19 treatment on Monday. The treatment is a hyperimmune immunoglobulin (IgG) product derived from convalescent plasma of volunteers who have recovered from COVID-19. Kamada's treatment is currently in an ongoing phase 1/2 clinical trial in Israel.